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Monoclonal antibodies (MAbs) against two major structural proteins of the cell-adapted Mebus strain of bovine
coronavirus
(BCV-L9) were produced and characterized.
Seven MAbs reacted with the peplomeric glycoprotein,
gplOO/S, while three MAbs reacted with the nucleoprotein
p53/N in Western blot analysis of BCV polypeptides.
MAbs
to gplOO/S reacted with discontinuous
epitopes of gplOO/S in Westerns under mild but not under standard denaturing
conditions. In contrast, MAbs to p53/N reacted in both types of Westerns, and those epitopes were thus continuous.
MAbs to p53/N failed to neutralize BCV infectivity,
while 4 MAbs to gplOO/S neutralized BCV effectively.
Cross
reactivity of MAbs to gplOO/S specified by five virulent wild-type strains and two high passage, cell-culture-adapted
strains in mildly denaturing Westerns and neutralization assays indicated that two epitopes were conserved in all seven
strains, while two epitopes of the avirulent strains were not detected in the wild-type strains. Non-neutralizing
MAbs of
gplOO/S reacted with all seven strains in Westerns with the exception of one MAb that was specific for the highly
cell-adapted strain BCV-L9.
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on the S and three domains on the HE glycoprotein (13).
Antigenic diversity among isolates of several groups
of coronaviruses was documented. MAbs to MHV-4
gpl80/90 revealed little conservation among isolates
(14). Comparison of TGEV strains with a panel of MAbs
evidences differential retention of epitopes (10, 11, 15).
Monoclonal antibodies to the S glycoprotein of FIPV
were used to distinguish virulent and avirulent FIPV
strains, and to demonstrate antigenic differences between FIPV and FECV strains (9, 16). Serological variation among 5 BCV strains was observed ( 17). Oral vaccination of newborn calves with attenuated BCV protected against infection by the virulent virus within 2-3
days postimmunization
of colostrum-deprived
calves
(18). However, the vaccine has not been completely
effective in field trials (19). We analyzed with a panel of
MAbs the cross-reactivity of gpl 00/S and p53/N specified by five virulent wild-type strains and two high pascell-adapted
strains,
which
includes
the
sage
currently used vaccine strain.
The cell culture-adapted prototype BCV-L9 was originally isolated in bovine fetal kidney (BFK) cells from diarrhea fluid of a calf (20). This virus was serially passaged
42 times in BFK cells, 16 times in bovine fetal brain
cells, 15 passages in bovine fetal spleen (BFS) cells,
and for 5-l 0 passages in human rectal tumor(HRT-18)
cells. Five other wild-type BCV isolates, initially maintained by calf inoculation, were adapted to HRT-18
cells from diarrhea fluid or intestinal mucosal scrapings
of calves with clinical diarrhea and electron micro-

Bovine coronavirus (BCV) is a member of the coronaviridae family that causes neonatal diarrhea, a disease
with substantial economic impact in the dairy and beef
cattle industries. The viral particle is spherical, enveloped with a diameter of around 100 nm, possessing a
single-stranded nonsegmented RNA genome of positive polarity. The viral particle is composed of sets of
four major structural proteins (1-7). These consist of
the peplomeric glycoprotein (gpl9O/S, gplOO/S), the
nucleocapsid protein (p53/N) and its apparent trimer
(p160/N), a family of small matrix glycoproteins (gp25/
M, gp26/M, p23/M), and the putative hemagglutinin
(gpl24/HE).
Protein processing studies in infected
cells indicated that the glycosylated precursor gpl90
is proteolytically cleaved to yield gplOO/S (4). GPlOO/S
was shown to be the predominant form of S for BCV as
two presumptive comigrating gplOO/S species or a
doublet band was reported (4, 5). A number of other
coronaviruses possess similar structural proteins that
are targets of the humoral antibody response. MAbs to
S of mouse hepatitis virus type 4 (MHV-4), transmissible gastroenteritis virus (TGEV), feline infectious peritonitis virus (FIPV), and feline enteric coronavirus (FECV)
neutralized respective virus infectivity (8- 12). Immunization of mice with purified S from MHV-4 protected
them against a challenge infection with the virus (8).
Neutralizing MAbs to S and HE glycoproteins of BCV
(Quebec strain) defined two distinct antigenic domains
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scopic evidence of coronavirus
infection (21, 22).
These strains are: LY-138 (Utah, 1965) BCV C-50 (Colorado, 1972) BCV-Miller (Colorado, 1974) BCVMeeker (Colorado, 1975) and BCV-Fisher (Colorado,
1980). The vaccine strain of BCV was cultured in HRT18 cells from the vaccine of Norden Laboratories
(Omaha, NE) (20,23). Specific markers of this strain are
currently not available. Importantly, cultivation of the
BCV wild-type filed strains remained difficult until it was
demonstrated that the cytopathic expression of BCVL9 in cultured bovine cells was enhanced by tt-ypsin
(24) and that HRT-18 cells were susceptible
to
BCV (25).
Plaques of BCV were selected by a method similar to
the one described by Takayama and Kim (26) and modified by Jimenez et al. (10) in a plaque assay described
earlier (24). The infected cultures were overlaid with 3
ml of 1.2% (w/v) agarose in DMEM (Dulbecco’s modified Eagle medium) containing 4 pg/ml final trypsin
concentration. A stock of virus was prepared after two
consecutive plaque purification passages. The BCV
was purified as described (27). MAbs were produced
against purified virus preparations from the prototype
BCV-L9 as described previously (28).
Sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) was performed in 12% slab gels
by the Laemmli procedure (29). Detailed procedures
for the analysis of BCV proteins by SDS-PAGE and
Western blot were described (5, 28).
Western blots were performed under mildly denaturing conditions according to Cohen eT al. (30). Briefly,
this technique involved the use of low concentration of
SDS (0.1 Yo) and no heat or reducing agent which allows retention of much native conformation and detection of discontinuous epitopes. The presence of antibodies neutralizing BCV infectivity in sera from naturally or experimentally infected calves, or ascitic fluid
was detected by the plaque neutralization test as described previously (13, 24).
Three independent cell fusions produced 200 different hybridoma lines which yielded in 10 cell lines selected on the basis of their reactivity with BCV-specific
proteins in Western blots performed under mildly denaturing and denaturing conditions. The most frequent
isotype was immunoglobulin
Gl (IgGl) (seven MAbs),
followed by IgM and IgG2a. The MAb titer, determined
by ELISA of ascitic fluids ranged from 103.6 to 104.5.
Seven MAbs reacted specifically with gplOO/S in
mildly denatured Westerns (Fig. l), but failed to react in
denatured Westerns (not shown). Three MAbs reacted
with nucleoprotein p53/N in mildly denatured westerns
(Fig. 1) and denatured Westerns (not shown). Four
MAbs to gplOO/S neutralized BCV effectively by exhibiting neutralization titers that were 160, 320, or 640.
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FIG. 1. Native Western blot analysis under mild denaturing conditions and polypeptide specificity of 10 anti-BCV monoclonal antibodies. Proteins of density gradient-purified
BCV-L9 preparations were
resolved by SDS-PAGE and transferred to nitrocellulose
membranes. The strips were incubated with MAbs 43F6. 3488, 43C2,
44, 38, 16. 31, 10, 36, and 46 in lanes 2 to 11, respectively. A blot of
reference serum showing reactivity with BCV structural proteins
(lane 1) is included for reference.

In contrast, all three MAbs to nucleoprotein
p53/N
failed to neutralize the virus infectivity (Table 1).
MAbs were reacted with proteins specified by five
wild-type strains originating from different geographical locations and isolated at different times, and with
two related cell-adapted strains in Westerns. The latter
group included the currently used vaccine strain and
its progenitor laboratory strain BCV-L9 (Table 1). MAbs
to p53/N reacted similarly against p53/N specified by
all strains in both Westerns. Three MAbs to BCV-L9
gplOO/S failed to react with gplOO/S specified by other
viral strains with the exception of antibodies 44 and 38
which reacted with the vaccine strain (Table 1). Specifically, three antigenic types of virus were distinguished.
One type was the cell-adapted Mebus strain BCV-L9
used as the immunogen for the isolation of the MAbs.
The second type was represented by the modified live
virus vaccine strain, which differed from the prototype
BCV-L9 through the loss of reactivity to MAb 31. The
third antigenic type included all five virulent wild-type
isolates, distinguished
by their failure to react with
MAbs 31, 38, and 44.
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TABLE 1
REACTIVIPIOF MONOCLONAL ANTIBODIESWITH BCV STRAINSIN WESTERNSAND NEUTRALIZATIONTESTS
BCV strains

MAbs
Anti-gpl 00
3488
16
43C2
43F6
44
38
31
Anti-p53
10
36
46

L9

Vaccine

+-+ <2Ob
+ <20
+ 640
+ 640
+ 640
+ 640
+ <20

+
+
+
+
+
+
-

+ <20
+ <20
+ <20

+ ND
+ ND
+ ND

ND
ND
320
320
320
320
ND

LY-138

Meeker

+
+
+
+
-

+
+
+
+
-

ND
ND
160
320
<20
<20
ND

+ ND
+ ND
+ ND

ND
ND
640
640
<20
<20
ND

+ ND
+ ND
+ ND

c-50

+
+
+
+
-

ND
ND
320
320
<20
<20
ND

+ ND
+ ND
+ ND

Miller

+
+
+
+
-

ND
ND
320
320
420
<20
ND

+ ND
+ ND
+ ND

Fisher

+
+
+
+
-

ND
ND
320
320
<20
<20
ND

+ ND
+ ND
+ ND

a Westerns were run under mildly denaturing conditions; + and - indicate positive and negative reaction in Westerns, respectively.
b Neutralization titers are expressed as the reciprocal of the dilution of ascites fluid that produced 50% reduction in plaque forming units (PFU);
100 PFU per test. ND, neutralization test not done.

The infectivity neutralizing ability of MAbs against
heterologous BCV strains was tested. MAbs 43F6 and
43C2 neutralized all strains, exhibiting small variations
in titers. In contrast, MAbs 38 and 44 neutralized the
avirulent BCV-L9 and vaccine strains but failed to neutralize the five wild-type strains (Table 1).
All MAbs to gplOO/S reacted in mildly denatured
Westerns but failed to react with gplOO/S in denatured
Westerns which reveals that the major antigenic domains of gplOO/S were composed of discontinuous
amino acids brought together by virtue of the folding of
the molecule in three dimensions. Furthermore, the
addition of a reducing agent abolished the antigenic
reactivity indicating that disulfide bonds were important in stabilizing the tertiary structure of gpl 00/S. Similar results were reported for gplOO/S specified by the
BCV Quebec strain (13).
MAbs to gplOO/S reacted exclusively with gplOO/S
and failed to detect its precursors gpl7O/S and gpl90/
S in Westerns. It is not clear whether gplOO/S represents the amino-terminal (S,) or carboxyl-terminal (S2)
component of the proteolytic cleavage products of S.
In contrast, MAbs to BCV (Quebec-strain) were reported to react with gplOO/S precursors and higher
molecular weight aggregates (13). The observed differences in reactivity may be due to the different conditions used to solubilize BCV viral proteins or may reflect viral strain-host cell differences in the relative
amounts of processed gplOO/S used to produce the
immunogens for the generation of the hybridomas.
Comparative reactivity of these sets of MAbs would
resolve these differences.

MAb cross-reactivity tests with different viral strains
revealed strong antigenic variation in gplOO/S among
virulent and avirulent strains. In contrast, MAbs to nucleoprotein p53/N cross-reacted with all strains.
Cross-reactivity of six out of seven MAbs with gpl 00/S
specified by the related avirulent vaccine and BCV-L9
strains infers that these glycoproteins folded into
nearly identical conformations. The failure of MAb binding to gplOO/S specified by the wild-type strains implies that their three-dimensional configurations differed significantly. Interestingly, one MAb failed to
react with the vaccine strain although it reacted with its
progenitor strain BCV-L9. A limited number of replication cycles of the virus in cell culture is evidently sufficient for the emergence of an antigenic variance.
MAbs to the nucleoprotein p53/N reacted in both
Westerns illustrating that their target epitopes were
composed of continuous amino acids located proximal
to each other, thus rendering these epitopes insensitive to denaturation.
Neutralization tests with MAbs to gplOO/S revealed
the presence of epitopes associated with virus neutralization. This is in agreement with findings for coronaviruses from other animals (4, 11, 37, 32) and the Quebec strain of BCV (13). Cross-neutralization studies
with MAbs to gplOO/S revealed that wild-type strains
were not neutralized by two MAbs. Conformational differences detected by the reactivity in Westerns are
thus within antigenic areas that are crucial for virus
neutralization. Similar observations were reported for
mouse hepatitis virus 4 (31, 33) and the transmissible
gastroenteritis virus (10, 11). It is conceivable that con-
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formational differences in gplOO/S of wild-type strains,
as compared to the vaccine stain, result in loss of neutralizing sites with subsequent loss of protection following vaccination. None of the five wild-type BCV strains
were cultivatable in bovine fetal spleen cells even in the
presence of trypsin (22). A unique plaque morphology
characterized each BCV strain grown in HRT-18 cells
(22). The epitopes to MAb 31, 38, and 44 appear to
reflect the wider host cell range of the highly cell-cultured adapted L9 and vaccine strains.
Glycoprotein S of coronaviruses is generally implicated in virus adsorption onto eukaryotic cells and in
cell fusion (5, 35). The biological differences in BCV
strains reported previously and the differences in the
reactivity of MAbs with BCV strains apparently reflect
changes in gplOO/S related to virulence and adaptation to cultured cells. Our findings highlight again that
gplOO/S is a major target of the humoral response, and
it may contain the majority of antigenic domains that
are targets for neutralizing antibodies.
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